<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Crown Bioscience Educational Webinar Series

Learn from our Experts!

Participate in Crown Bioscience's 2023 educational webinar series to expand your knowledge and support your preclinical research and drug development. This series covers various topics, including oncology, immuno-oncology, immune-mediated inflammatory disease, biomarkers, bioinformatics, databases, and more. Register now for our upcoming live webinars, or watch our previous webinars today!



Upcoming Webinars

September Webinars

Accelerate IO Drug Development with a Fast, Cost Effective, and Powerful Screening

Thursday, September 28, 2023 | 10:30 AM ET and 1:00 PM ET

In this webinar Dr. Bailey Zhong will discuss common IO drug development challenges and how a large-scale in vivo screen can be used to overcome these challenges. There will also be time for Q &A.

Learning Objectives
  • How this platform enables clients to efficiently determine how to progress their preclinical drug development efforts or conduct early-stage drug screening.

  • The different immuno-oncology models offered in MuScreen that fit specific application scenarios due to their unique features.

  • Why MuScreen’s model panel offers an ideal range of immuno-oncology interactions, supporting mechanism of action studies.

  • How the panel is highly capable of discovering I/O biomarkers when used in conjunction with downstream analysis.
About Our Speaker

Bailey Zhong, PhD, Senior Manager of Scientific Engagement, Crown Bioscience (APAC regions)

Bailey (Yixiang) Zhong is the Senior Manager of Scientific Engagement for the APAC territory at Crown Bioscience. He specializes in providing IND-facing pharmacological solutions for new cancer drugs, as well as pre-clinical efficacy and MOA assays. Bailey joined Crown Bioscience after completing his PhD and post-doctoral training at Hanyang University in Korea. With ten years of research experience in multiple life science fields, including oncology, stem cell, organoid, and bioinformatics, Bailey has led over 150 external studies at Crown Bioscience and contributed to more than 30 sponsors’ IND/CTA submission projects. He has also published 5 peer-reviewed scientific articles. Bailey’s expertise and experience make him a valuable asset to the Crown Bioscience team.

Large-Panel Organoid Screening: Bridging Reproducibility and Clinical Relevance in Oncology Drug Discovery

September 29, 2023
Session 1: 4:00 pm CST, 10 am CET
Session 2: 8:00 am PT, 11:00 am ET, 5:00 pm CET

Join us for a pivotal discussion with Mariusz Madej on "Pan-cancer 'Assay-ready' Organoid Drug Screening." With 95% of anticancer drugs failing before clinical stages, Madej highlights a game-changing approach using patient-derived organoids in high-throughput drug screening. These 3D tumor models offer better translatability than traditional 2D cell lines. Delve into a case study on the Assay-ready (AR) organoid platform, which streamlines timelines and costs in drug discovery. Whether you're in research, pharmaceuticals, or keen on cancer treatment advancements, this talk promises transformative insights into the future of cancer drug development.

Learning Objectives
coming soon
About Our Speaker
coming soon

Watch Now

Selecting the Best Mouse Model for Your Preclinical IBD Research: Novel and Established Colitis Mouse Models

The search for effective treatments for inflammatory bowel disease (IBD) continues through the latest advances in preclinical research using different types of IBD mouse models. However, choosing a mouse model for IBD preclinical studies is not always straightforward and is a prerequisite for reliable outcomes. We invite you to join our Tech talk to learn more about this topic.

Learning Objectives
  • Compare the advantages and disadvantages of different irritable bowel disease models

  • Understand the use of genetically engineered mouse colitis models to test human biologics

  • Gain insight into the efficacy of traditional and novel therapeutics used in mouse models and their response in clinic
About Our Speaker

Astrid Doerner, PhD, Director of Inflammation and Immunology, Crown Bioscience

Dr. Doerner completed a Doctor of Sciences in Biochemistry at the Max-Planck Institute of Molecular Physiology in Germany. Prior to that, she received a BS and MS in Chemistry from the University of Dortmund. Dr. Doerner had a postdoctoral fellowship at both the Scripps Research Institute in La Jolla and the Division of Allergy, Rheumatology and Immunology, UCSD & Veterans Medical Research Foundation in La Jolla. Prior to joining Crown Bioscience in 2019, Dr. Doerner also worked as an Assistant Project Scientist at the Division of Allergy, Rheumatology and Immunology, UCSD & Veterans Medical Research Foundation.

Dr. Dorner’s research has focused on innate immunity in host defense and inflammation as well as acute and chronic allergic Asthma.

Navigating Cancer Model Databases for Optimized Model Selection

Join us for an insightful and interactive workshop where we will showcase how to utilize free databases (HuBase™,OrganoidBase™, MuBase®, XenoBase®)  to find the best models for your preclinical oncology studies. This workshop is designed to equip researchers, scientists, and professionals in the field of oncology with the necessary knowledge and tools to make informed decisions and drive successful preclinical research.

Learning Objectives
  • Identify the appropriate database to find models based on your research needs.

  • Make data-driven decisions on models by reviewing available information (e.g. patient clinical history, imaging, genomic and proteomic data).

  • Use basic and advanced filtering and search functions to confidently choose models by target or other features.
About Our Speaker

Adrien Mossu, PhD, Senior Scientific Account Manager, Scientific Engagement

Dr. Adrien Mossu is an accomplished Sr. Scientific Account Manager with a strong background in immunology. During his MSc and PhD, Adrien delved into resolving inflammatory episodes and quickly became fascinated by the intricacies of cellular interactions, realizing their crucial role in targeting specific disorders. His postdoc work focused on multiple sclerosis, leading him to develop innovative physiological on-a-chip and in vitro models to study immune cells from patients. Driven by the desire to support fellow scientists, Adrien joined a preclinical immuno-oncology CRO as a Study Director, collaborating closely to drive projects forward. Enthusiastic about making a difference, Adrien joined Crown Bioscience in 2021, now devoted to scientifically empowering customers' preclinical research in oncology and inflammation.

Functional Screening of Patient-Derived Organoids Using High-Content Imaging

Watch our exclusive webinar and discover how you can revolutionize your cancer research and drug discovery efforts using patient-derived organoids and high-content imaging.

Learning Objectives
  • Expert guidance on selecting the most suitable in vitro and in vivo models for your specific research needs, optimizing drug screening, and conducting efficient efficacy testing.

  • OrganoidBase™ - our free, extensive resource of patient data, which includes IC50 values, light microscopy, histopathology, and genomic information.

  • Case studies that demonstrate the power of functional screening using high-content imaging on a colorectal cancer PDO biobank. Witness how this approach can drive impactful discoveries and advance your research objectives.

  • Cutting-edge IO assays with organoids, enabling flexible immune cell profiling and treatment evaluation. These advanced techniques can provide deeper insights into the efficacy and mechanisms of immunotherapies.
About Our Speaker

Sumithra Urs, PhD, Director, Scientific Engagement

Sumithra’s post-doctoral work on role of Notch signalling in human breast cancer fueled her interest in focusing on oncology and modelling. Prior to joining industry, she was at the University of Michigan, Translational Oncology Program, focused on pancreatic cancer research and establishing PDX models and 3D microtumors for drug screening. Sumi has more than six years of preclinical oncology experience using syngeneic mice tumor models, xenografts, and 3D platforms. As a subject matter expert in preclinical oncology, her experience includes pharmacology, immuno-oncology, CAR T/adoptive cell therapy, radiotherapy, and combination therapies. Sumi’s academic training as well as CRO experience in the preclinical space helps her understand client’s requirements and offer suggestions on model selection and study design specific to enable drug screening, efficacy and help in advancing to clinical trials.

Establishment of Next Generation Pretreated PDX Models: A tool for Precision Medicine

There is an urgent need for more clinically-relevant PDX models reflecting current patient populations and treatments that are failing in the clinic today due to drug resistance. Participate in this webinar to learn about Crown Bioscience's establishment and validation of pretreated PDX models, suitable for the development of next-generation therapeutics.

Learning Objectives
  • The establishment of pretreated PDX models with detailed treatment histories including KRAS inhibitors and checkpoint inhibitors.

  • The characterization and validation of pretreated PDX models, including efficacy data

  • Various preclinical applications (mouse clinical trials, databases, genomics, biomarker analysis) for the development and assessment of next generation oncology drugs.
About Our Speaker

Rekha Pal, PhD, Senior Director, Scientific Engagement

Dr. Pal is a trained cancer biologist with a focus on preclinical cancer therapeutics, immune-oncology, cancer signaling, and tumor microenvironment. She earned her PhD in Biochemistry from Central Drug Research Institute, India.

She joined the University of Pittsburgh as a postdoctoral researcher and moved onto research faculty. She has extensively worked in stem cell biology and translational cancer research using patient’s blood, tumor and bone marrow samples with a correlation of clinical data for the targeted biomarker identification with the drug treatment.

She joined National Surgical Adjuvant Breast and Bowel project (NSABP), a clinical trial supportive group to develop strategies for preclinical evaluation of test agents to support NSABP’s phase I/II clinical trials for colon and breast cancer. She also led the effort of organoids generation from the PDX tumor tissue to screen drugs or drug combinations as personalized medicine. Rekha represented NSABP as a translational research committee member on B-50 Katherine-B027938 Roche study.

Dr. Pal’s role at Crown Bioscience is to direct scientific engagement with pharmaceutical companies, academic scientists, and clients. She helps indecision making with the goal of high scientific input in study design and model execution. She exchanges scientific information for existing and new opportunities between Business Development and the scientific team, generates protocols, study design and proposals to define projects/ studies.


Advancing Proteomics Profiling in Tumor Xenograft Models: Overcoming Challenges and Accelerating Oncology Drug Discovery

MS-based proteomics has gained significant traction in translational research, enabling researchers to analyze proteins at an unprecedented level of detail. At Crown Bioscience, we understand the challenges faced in proteomic profiling, especially when it comes to human tumor xenografts, as distinguishing human and mouse proteins in these models can be complex.

Learning Objectives
  • Overcome inaccuracies in traditional xenograft proteomic profiling

  • Achieve superior proteomic profiling with our innovative approach

  • Advance proteomic profiling using the latest trending technologies
About Our Speaker

Binchen Mao, PhD, Principal Scientist, Data Science and Bioinformatics

Dr. Binchen Mao obtained his M.S. in Biostatistics and Ph.D. in Biochemistry from Rutgers University and has published numerous articles in prestigious journals such as Nature, Nature Methods, JACS, and Structure.

Dr. Mao joined Crown Bioscience in 2016 and currently holds the position of Principal Scientist in the Data Science and Bioinformatics Department. With extensive expertise and work experience in the fields of biostatistics, biomarker analysis, and structural biology, Dr. Mao brings a wealth of professional knowledge to his role.


Reserve your seat today!